May 18, 2018
Rain Therapeutics Inc.
Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, closed an $18.4M Series A financing. Fortis corporate attorneys represented Rain in the transaction. https://www.globenewswire.com/news-release/2018/05/21/1509292/0/en/Rain-Therapeutics-Closes-18-Million-Series-A-Financing.html
